SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix announced that the U.S

CorMedix Inc. · 8-K filed Jun 8, 2026 at 08:45 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 8, 2026 at 08:45 ET

CorMedix announced that the U.S. Court of Appeals for the Federal Circuit affirmed the district court's judgment that Nexus Pharmaceuticals' generic minocycline product infringes two of CorMedix's MINOCIN patents and rejected Nexus' invalidity challenge. The Federal Circuit also upheld the permanent injunction barring Nexus from marketing its generic product prior to patent expiration. This ruling removes a key near-term generic threat to MINOCIN, CorMedix's primary commercial product, and strengthens its intellectual property position.

  • Federal Circuit affirmed district court judgment that Nexus' generic minocycline product infringes two CorMedix MINOCIN patents.
  • Federal Circuit rejected Nexus' invalidity challenge.
  • Permanent injunction barring Nexus from marketing its generic product prior to patent expiration was affirmed.
  • Patents-at-issue are FDA Orange Book listed and protect MINOCIN for Injection.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access